CHOP方案与FCD方案治疗初治惰性淋巴瘤的疗效和安全性研究  

Efficacy and safety of CHOP and FCD programmes on the initial treatment of indolent lymphoma

作　　者：苏铭俊[1] 张呈[1] 容庭杰 

机构地区：[1]江门市新会人民医院血液科,广东新会529100

出　　处：《慢性病学杂志》2016年第5期512-514,共3页Chronic Pathematology Journal

摘　　要：目的探讨环磷酰胺+多柔比星+长春新碱+泼尼松联合化疗(CHOP)方案和氟达拉滨+环磷酰胺+地塞米松联合化疗(FCD)方案治疗初治惰性淋巴瘤的疗效和安全性。方法回顾性分析江门市新会人民医院2012年4月—2015年4月入院的50例行初治惰性淋巴瘤治疗的患者临床资料,按治疗方案的不同分为两组,每组25例。CHOP组患者给予环磷酰胺+多柔比星+长春新碱+泼尼松联合化疗(CHOP方案),FCD组患者给予氟达拉滨+环磷酰胺+地塞米松联合化疗(FCD方案),比较两组患者治疗效果及骨髓抑制情况等。组间率的比较采用χ2检验。结果 CHOP组治疗后病情完全缓解(CR)5例、部分缓解(PR)4例、稳定(SD)8例、进展(PD)5例,有效率36.00%(9/25);对照组分别为2、3、8、8例和20.00%(5/25),差异无统计学意义(P>0.05)。CHOP组患者骨髓抑制Ⅲ~Ⅳ度情况及骨髓总抑制情况均低于FCD组患者,差异有统计学意义(P<0.01)。结论 CHOP方案与FCD方案对初治惰性淋巴瘤的治疗效果无显著性差异,但FCD组患者骨髓抑制情况明显增强。Objective To investigate the efficacy and safety of CHOP and FCD programmes in the treatment of newly diagnosed indolent lymphoma. Method A total of 50 patients with initial treatment of indolent lymphoma in Xinhui People's Hospital from April 2012 to April 2015 were retrospectively analyzed. They were divided into two groups of 25 patients each. CHOP group were treated with combined chemotherapy of cyclophosphamide, doxorubicin, vincristine and prednisone. FCD group were treated with combined chemotherapy of fludarabine, cyclophosphamide, dexamethasone. Efficacy and myelotoxicity between the two groups were compared with chi-square test. Results After treatment of CHOP, 5 patients were complete remission(CR); 4 patients were partial remission(PR); 8 patients were stable(SD); 5 patients were progress(PD). The effective rate in the CHOP group was 36.0%. After treatment of FCD, there were 2 patients with CR; 3 patients with PR; 8 patients with SD; 8 patients with PD. The effective rate in the FCD group was 20.0% which wasn't significantly different with that in the CHOP group(P>0.05). The incidence rates of Ⅲ-Ⅳ degree and total myelotoxicity in the CHOP group were all significantly lower than those in the FCD group(P<0.01). Conclusions There was no significant difference between CHOP programme and FCD programme on the initial treatment of indolent lymphoma, but bone marrow suppression of FCD is more obvious.

关 键 词：初治惰性淋巴瘤 CHOP方案 FCD方案 疗效 安全性 

分 类 号：R733.1[医药卫生—肿瘤]